Ampersand capital news. Tel: +31-20-767-1773 Email: info@ampersandcapital.
Ampersand capital news 50 per share in cash. Tel: 781-239-0700 Email: info@ampersandcapital. Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Aug 21, 2024 · Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. History; Core Values; Team; Investment Focus. His last employment was as Managing Director – Research at BofA–Merrill Lynch where he worked for 11 years before founding Ampersand. January 9, 2015. ’s 2024 Founder-Friendly Investors list, which honors the private equity and venture capital firms with a proven track record for building strong partnerships with Oct 29, 2024 · News October 29, 2024 Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to Read the latest news and press releases for Ampersand Capital Partners. Tel 781-239-0700 Fax 781-239-0824 One Post Office Square, Suite 2900 Boston, MA 02109 Tel: 781-239-0700 Fax: 781-239-0824 Email: info@ampersandcapital. Tel: +31-20-767-1773 Email: info@ampersandcapital. One Post Office Square, Suite 2900 Boston, MA 02109. ’s 2024 List of Founder-Friendly-Investors. Aug 22, 2022 · News August 22, 2022 Ampersand Closes Oversubscribed Fund at $1. We have been at the forefront of transformative investments in the healthcare and life sciences markets. Ampersand News Nov 6, 2024 · Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12. 2 Billion Hard Cap. The strategic combination of Flagship and IPS creates a full repertoire of biomarker lab and analytic services to advance precision therapeutic development and adds a state-of-the-art Mar 19, 2024 · Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Biologos Feb 12, 2024 · News February 12, 2024 David Bruning Named Chief Executive Officer of StageBio. Mar 19, 2024 · Ampersand's deep industry expertise, broad network, and capital resources will enable Biologos to accelerate its growth strategy through the development of new products and its expansion into Ampersand Capital Partners One Post Office Square, Suite 2900 Boston, MA 02109 United States. Dec 2, 2024 · About Ampersand Capital Partners. Jan 1, 2025 · Stay up-to-date on the latest news and press from Ampersand Capital Partners and its life sciences portfolio. Wellesley, MA, August 22, 2022 – Ampersand Capital Partners is pleased to announce the closing of the firm’s latest fund, Ampersand 2022 (“AMP-22”) Limited Partnership, with $1. Orpington, UK, March 13 th, 2024 – Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Specac Limited (“Specac”), an industry leader in the design and manufacture of spectroscopy By 2015, GENEWIZ had organically evolved into a global business with a strong operational presence in the U. Hidde Van Kerckhoven joined Ampersand Capital Partners in 2022. , Japan, and China, boasting annual revenues close to $60 million. Read the latest news and press releases for Ampersand Capital Partners. com Ampersand Capital Partners has built a 30-year history of accelerating growth-oriented life sciences companies and empowering founders and their brands in becoming industry leaders. Prior to joining Ampersand, he was a member of the healthcare investment team at Gimv where he was actively involved in various platform acquisitions and add-ons in the healthcare services and life sciences industries. Today, Ampersand focuses exclusively on growth equity investments in lower to middle market healthcare companies, primarily as the first institutional investor in founder-owned businesses. It was then that Ampersand Capital Partners first approached Liao and Sun, offering a minority capital investment to help accelerate the company’s growth. His professional career started with ICICI, followed by stints with HSBC Securities, Paribas Capital Markets and IDFC-SSKI Securities. History; News. Aug 31, 2022 · This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies. Mt. Guildford, UK and Durham, NC – January 26 th, 2024 – MedPharm, a global topical and transdermal CDMO, today announced several Board changes, including the appointment of Patrick Walsh as Executive Chairman. Moonachie, NJ – June 23, 2022 – Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today an investment in Sterling Medical Devices, a leading provider of design, development and regulatory services to the medical May 16, 2024 · Wellesley, MA, May 16, 2024 /PRNewswire/ — For the second consecutive year, Ampersand Capital Partners is ranked #1 globally by HEC Paris-DowJones for growth capital private equity performance. S. Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. 2 billion in limited partner commitments. HEC Paris analyzed performance data from 106 Growth Capital firms and the 279 funds they raised between 2010 and 2019 with an aggregate equity volume Dec 2, 2024 · About Ampersand Capital Partners. Dec 2, 2024 · Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of its previously Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics’ PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem. Nov 4, 2024 · News November 4, 2024 Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to When the COVID-19 pandemic emerged, Ampersand played a crucial role in positioning Nexelis to support vaccine development efforts. Jackson, VA, February 12, 2024 /PRNewswire/ — StageBio, a leading provider of GLP-compliant histology, pathology, image analysis and archiving services for both preclinical and clinical research, is pleased to announce the appointment of David Bruning as Chief Executive Officer. com. Jun 23, 2022 · News June 23, 2022 Ampersand Capital Partners Invests in Sterling Medical Devices. May 16, 2024 · For the second consecutive year, Ampersand Capital Partners is ranked #1 globally by HEC Paris-DowJones for growth capital private equity performance. com Mar 19, 2024 · News March 19, 2024 Ampersand Capital Partners Acquires Biologos. Nov 6, 2024 · Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12. Amsterdam. Oct 31, 2024 · News October 31, 2024 Ampersand Capital Partners Named to Inc. Glendale Heights, Illinois, March 19 th, 2024 – Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Biologos LLC (“Biologos”), a full-service manufacturer of custom and standard cell Founded in the late 1980s, Ampersand Capital Partners began investing in life sciences companies in the early 1990s. Boston, MA, October 31 st, 2024 – For the third consecutive year, Ampersand Capital Partners has been named to Inc. Feb 26, 2024 · News February 26, 2024 MedPharm Welcomes New Board Members, Appoints Industry Veteran Patrick Walsh as Executive Chairman. January 9, 2015 Ampersand Exits ChanTest Mar 13, 2024 · News March 13, 2024 Ampersand Capital Partners Acquires Specac, Ltd. Jul 1, 2024 · News July 1, 2024 Genezen to Aquire uniQure’s Commercial Gene Therapy Manufacturing Operations in Lexington, MA. With the globalization plan for the brand firmly in place, Ampersand’s team helped Nexelis pivot its strategy and develop lab capabilities to capitalize on the urgent need for COVID-19 vaccine development and testing, leveraging its expertise in immunology and . Ampersand Capital Partners Gustav Mahlerplein 105-115, 26th floor 1082 MS Amsterdam The Netherlands. About Us. Laboratory Products; News; Contact Dec 4, 2024 · San Sebastian, Gipuzkoa, Spain, December 4 th 2024 /PRNewswire/ — VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in the life sciences and healthcare sectors. xgfohcsgwsgevlqzicekflpxxousmkjbttktdpgfzzbxyvowowtvjoxmtkowpc